ddd FIXED QUOTES!!!FIXED QUOTES!!!!!On November 18, 1971, Judah Folkman, a little-known surgeon from New England, published a scientific article documenting the dependence of tumors on growth of new blood vessels from the body, as well as the therapeutic implications arising from his new discovery. Dr. Folkman proposed that the tumor recruited these blood vessels to support itself. The process by which tumors take these blood vessels out of the body is known as “angiogenesis.” The publication of Dr. Judah Folkman's article entitled “Tumor Angiogenesis: Therapeutic Implications” (New England Journal of Medicine, 1971) influenced cancer research by establishing a new field of study with treatment possibilities that resolve many age-old therapeutic dilemmas. Angiogenic therapy offers a universal therapeutic approach for all tumors, better mechanisms to diagnose cancer early, and even answers to previously unexplained phenomena, such as tumor dormancy. Judah Folkman was born in Cleveland, Ohio in 1933. He graduated from Ohio State University in 1953. University and continued to Harvard Medical School. Dr. Folkman later became a surgeon and made important discoveries in a number of medical fields before becoming interested in cancer. For example, he was responsible for a pioneering role in the field of controlled drug release, which in turn led to the invention of the popular contraceptive “Norplant”. During the 1960s, Dr. Folkman was drafted into the Navy and began investigating the possible use of a blood substitute that could be stored for long periods of time and then administered to the wounded. After completing his assignment, Dr. Folkman began experimenting in his spare time, investigating cancer and the biology of solid tumors. ...... middle of paper ...... without tumor development?" VEGF Research. Gentech, 2010. Web. April 27, 2010. Naumov GN, Akslen LA, and Folkman J. "Role of angiogenesis in dormancy of human tumor: animal models of the angiogenic switch". Cell cycle 5.16: page n. Abstract. Pubmed. Network. April 27, 2010. Pacific Life Insurance Company. “Cancer Biomarkers: Still Controversial.” Pacific Life. Pacific Life Insurance Co., 2010. Web. 27 April 2010. .Tosetti, Francesca, et al. “‘Angioprevention’: Angiogenesis as a Common and Key Target cancer chemopreventive agents." FASEB 16 (2002): 2-14. The FASEB diary. Network. April 27. 2010. .